Recent Company News

• 02:00 PM ET Oct 12, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 5-Oct

• 07:48 PM ET Oct 09, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 09:08 PM ET Oct 08, 2026
  

  Quick Take: CSL +1.3% on Haemonetics' plasmapheresis platform rollout of newer collection system (A$183.91, +2.45)

• 05:19 PM ET Oct 08, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:30 AM ET Oct 08, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:19 AM ET Oct 08, 2026
  

  Haemonetics comments on CSL's rollout of the plasmapheresis platform - 8-K ($101.71, 0.00)

• 04:04 AM ET Oct 08, 2026
  

  CSL expects to complete rollout of Haemonetics' plasmapheresis platform across US plasma collection centres by end of 2027 (A$181.46, 0.00)

• 11:34 PM ET Oct 05, 2026
  

  Street Takeaways - CSL exclusive collaboration with Alentis Therapeutics (A$178.22, +1.23)

• 02:01 PM ET Oct 05, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 28-Sep

• 05:30 PM ET Oct 04, 2026
  

  CSL enters into agreement with Alentis Therapeutics to co-develop and co-promote lixudebart; CSL to make initial payment of $355M (A$175.35, 0.00)